Back to News
Market Impact: 0.2
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Source: benzinga.com
Healthcare & Biotech
Agomab Therapeutics reported results from the 48-week open-label extension of its Phase 2a STENOVA trial evaluating ontunisertib in fibrostenotic Crohn's disease. The article provides no efficacy, safety, or financial data, limiting assessment of the trial's investment significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
AGMB0.20
More News
- One of our most recent defensive buys cleared a hurdle and its stock jumped
- Cullinan initiates FDA filing for lung cancer drug zipalertinib
- Moderna to replace Warner Bros Discovery on Nasdaq 100
- Why McKesson Stock Soared More Than 5% Higher Today
- This biotech making precision medicines for cancer could nearly triple, says JPMorgan
- The Dow's rough month, Micron's revenue surge, Google launches Gemini 4 and more in Morning Squawk